Parham Eshtehardi MD
LightNews LightNews
banner
cardioobdoc.bsky.social
Parham Eshtehardi MD
@cardioobdoc.bsky.social
2.4K followers 1.2K following 1.4K posts
Preventive, Imaging, CardioOB Cardiologist & Scientist • Dad • Husband of a Stroke & Cancer Survivor Hero • Emory Trained • Atlanta, GA
#CardioSky #CardioObstetrics #ACCRepOB #ACCCardioOB

🔗 bit.ly/MyResearchPubs
Posts Replies Media Videos
Pinned
cardioobdoc.bsky.social
Parham Eshtehardi MD @cardioobdoc.bsky.social · Nov 22
#Skytorial for #CardioSky #MedSky newcomers
1/2

🦋 Follow #CardioSky community by using starter packs:
Cardio Journals & Societies
go.bsky.app/FfE1QRm
CardioSky I
go.bsky.app/562nfhZ
CardioSky II
go.bsky.app/R2XckyG

🦋 Add label "Cardiology" to your profile w/labeler
bsky.app/profile/meds...
Reposted by Parham Eshtehardi MD
accintouch.bsky.social
#AHA25: ACC Vice President Roxana Mehran, MD, FACC, shares insights on groundbreaking cardiometabolic therapeutic trials, including highlights from the VESALIUS-CV study.

Get the full details here: https://bit.ly/4oBNohQ

#cvPrev #cvLipids #ACCAnywhere #CardioSky #MedSky
November 8, 2025 at 7:51 PM
Reposted by Parham Eshtehardi MD
accintouch.bsky.social
MAPLE-HCM: Patients with oHCM treated with aficamten saw superior benefits in #heartfailure symptoms, exercise capacity, LVOT gradient and overall health status when compared to metoprolol.

Learn more: https://bit.ly/47wIVqD

#AHA25 #JACC #HCM #cvHCM #CardioSky #MedSky @jaccjournals.bsky.social
November 8, 2025 at 8:40 PM
Reposted by Parham Eshtehardi MD
ctopriceanu.bsky.social
🚨New at #AHA25 & in #JACC: In the MAPLE-HCM trial, those with obstructive #HCM treated with aficamten showed superior improvements vs. metoprolol in:

🫀HF symptoms
💪 Exercise capacity
⚡LVOT gradient
💬 Health status

Read more: tinyurl.com/yez2ybss

@accintouch.bsky.social @jaccjournals.bsky.social
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multi-Domain, Patient-Level Analysis of the MAPLE-HCM Trial:
www.jacc.org
November 8, 2025 at 8:52 PM
Reposted by Parham Eshtehardi MD
ahajournals.bsky.social
See what's happening at the American Heart Association Journals! #AHA25

Sign up for alerts for the Switchboard blog at AHAJournals.org
November 8, 2025 at 9:04 PM
Reposted by Parham Eshtehardi MD
accintouch.bsky.social
Studies like OCEAN from #AHA25 are reshaping strategies for managing #AFib, exploring topics like ongoing anticoagulation post-catheter ablation; optimal antithrombotic approaches after #cvPCI; and LAAC vs. medical therapy in high-risk patients.

More ➡️ https://bit.ly/47vGSTD #CardioSky #MedSky
November 8, 2025 at 9:30 PM
Reposted by Parham Eshtehardi MD
accintouch.bsky.social
TOP findings from #AHA25 found a liberal transfusion strategy did not reduce death or major ischemic outcome rates compared w/ a restrictive strategy in patients at ⬆️ risk of a cardiac event following major vascular or general surgery.

Get the details ➡️ https://bit.ly/4nMHXeD #CardioSky #MedSky
November 8, 2025 at 10:40 PM
Reposted by Parham Eshtehardi MD
nilskremermd.bsky.social
Proud to share our new CIRCULATION paper, released alongside our #AHA2025 presentation: Sotatercept rapidly lowers pulmonary pressures and RV afterload within hours.

🔗 www.ahajournals.org/doi/10.1161/...

#AHA2025 #Circulation #PAH #RVFunction #Sotatercept #PeoplesVentricle
Acute Hemodynamic Effects of Sotatercept | Circulation
www.ahajournals.org
November 8, 2025 at 11:12 PM
Reposted by Parham Eshtehardi MD
jama.com
In this pivotal phase 3 RCT, lorundrostat lowered blood pressure in adults with uncontrolled or treatment-resistant hypertension on multiple antihypertensive medications.

#MedSky #RCT

https://ja.ma/4nvMfbu
Figure 2. Changes in Office Blood Pressure From Randomization (Baseline) toWeek 6
June 30, 2025 at 3:20 PM
Reposted by Parham Eshtehardi MD
springermedicine.com
#MedNews - Intracoronary infusion of Wharton’s jelly derived mesenchymal stem cells significantly reduces the incidence of #HeartFailure in patients with a first #STEMI.

Full story 👉 buff.ly/DKumUVw

#CardioSky
Intracoronary mesenchymal stem cells reduce heart failure risk after STEMI
Intracoronary infusion of Wharton’s jelly derived mesenchymal stem cells significantly reduces the incidence of heart failure in patients with a first STEMI.
buff.ly
November 8, 2025 at 11:54 AM
Reposted by Parham Eshtehardi MD
ahajournals.bsky.social
Whether you are navigating your first peer reviewer assignment, preparing your first manuscript for publication, or are looking to engage with peers, American Heart Association Journals have opportunities for you. #AHA25

Find out more here: ahajournals.org/early-career
November 8, 2025 at 2:07 PM
Reposted by Parham Eshtehardi MD
ahajournals.bsky.social
The American Heart Association Journals Publishing Guide is always available for download. Look for an overview of publishing policies and exciting highlights of each journal. #AHA25

Get the Pub Guide and more at the Author Hub: https://www.ahajournals.org/author-hub
November 8, 2025 at 2:16 PM
Reposted by Parham Eshtehardi MD
scainews.bsky.social
🩸Bleeding remains a serious complication after #TAVR, but a variety of strategies are helping reduce these risks. Learn how teams are refining access techniques, antithrombotic regimens, and risk stratification in this Cardiovascular Business article ➡️ https://ow.ly/9tZl50XniWI

#CardioSky
How to minimize bleeding risks after TAVR
Bleeding events remain a serious complication after TAVR. By identifying high-risk patients early and planning ahead, however, care teams can keep them to a minimum.
ow.ly
November 8, 2025 at 3:01 PM
Reposted by Parham Eshtehardi MD
accintouch.bsky.social
2️⃣ late-breaking science presentations highlight new treatments for severe hypertriglyceridemia at #AHA25.

Read how the novel DR10624 medication reduced triglyceride levels ➕ liver fat, & about the benefits of olezarsen in ↘️ pancreatitis. 🔗 https://bit.ly/47xGfch

#CardioSky #MedSky
November 8, 2025 at 3:16 PM
Reposted by Parham Eshtehardi MD
accintouch.bsky.social
CRISPR-Cas9 ➡️ First-in-Human trial presented at #AHA25 suggests one-time infusion of an investigational CRISPR-Cas9 therapy targeting ANGPTL3 is safe & can reduce both LDL cholesterol & triglycerides.

Read the ACC News Story for more: https://bit.ly/47Nfb7O

#cvLipids #CardioSky #MedSky
November 8, 2025 at 3:30 PM
Reposted by Parham Eshtehardi MD
accintouch.bsky.social
VESALIUS-CV results show evolocumab reduced the risk of first cardiovascular events among patients with atherosclerosis or diabetes and without a previous #cvMI or #stroke compared with placebo.

Read more in our #AHA25 coverage: https://bit.ly/4oBNohQ

#CardioSky #MedSky
November 8, 2025 at 4:15 PM
Reposted by Parham Eshtehardi MD
ahajournals.bsky.social
Engage with the editors of American Heart Association Journals every day at #AHA25! These interactive sessions will provide invaluable insights into the latest trends, future directions, and the editorial process.

Go to https://www.ahajournals.org/AHASessions and mark your calendars today!
November 8, 2025 at 5:19 PM
Reposted by Parham Eshtehardi MD
escardio.bsky.social
How should ApoB and Lp(a) be used as core measures to assess cardiovascular risk?

Join experts Allan Sniderman, George Thanassoulis and Michael Pencina as they unpack the power of these biomarkers – and what they mean for prevention strategies.

Listen now👉 bit.ly/3LjJWcC

#ApoB #LipoproteinA
October 22, 2025 at 9:52 AM
Reposted by Parham Eshtehardi MD
escardio.bsky.social
The world of cardiovascular imaging comes together this December at #EACVI2025 in Vienna.

Register by 31 October to save, explore the Scientific Programme, and get ready to fine-tune your expertise at the most practical imaging congress https://ow.ly/9BUg50Xhpe9

📍 Vienna, 11–13 December

#EACVI
October 24, 2025 at 10:01 AM
Reposted by Parham Eshtehardi MD
escardio.bsky.social
Explore the science shaping the future of myocardial & pericardial care at M&PD 2025!

Join global experts for the annual meeting of the ESC Working Group on Myocardial & Pericardial Diseases in Trieste, Italy, from 28–29 Nov
Register by 31 Oct to save https://ow.ly/uHIt50Xg98v

#ESCardioMPD2025
October 24, 2025 at 2:02 PM
Reposted by Parham Eshtehardi MD
escardio.bsky.social
Create real-world change in preventive cardiology! 💚

Abstract & clinical case submissions are open for #ESCPrev26 – the global stage where next-generation prevention strategies take shape.

Submit your work today 👉 https://bit.ly/3L6Rf7C

#EAPC_ESC
October 27, 2025 at 9:01 AM
Reposted by Parham Eshtehardi MD
escardio.bsky.social
🎙️ New #ESCCardioTalk

Join Jean-Benoit Le Polain de Waroux & Maarten De Smet as they unpack arrhythmic risk and advanced heart failure in dilated cardiomyopathy – a deadly tango you don't want to miss.

🔗 Listen here: https://bit.ly/47vhTyF

#Cardiology #HeartFailure #Arrhythmias
October 27, 2025 at 11:01 AM
Reposted by Parham Eshtehardi MD
escardio.bsky.social
Heart Failure care is advancing faster than ever; be part of the evolution at #HeartFailure26

📢 Submit your abstract or clinical case to influence the new standards in prevention, diagnosis, and treatment

Deadlines: abstracts: 8 January, clinical cases: 20 January https://bit.ly/49oGmrM

#HFA_ESC
October 28, 2025 at 8:24 AM
Reposted by Parham Eshtehardi MD
escardio.bsky.social
#ACVC26 abstract submission deadline extended, giving you more time to share your work & shape practice in acute care

Bring your science to a community built on teamwork, learning, & action

Deadlines: Abstracts: 4 Nov | Clinical cases: 6 Nov https://bit.ly/4hJQzBh

#ACVC_ESC
October 30, 2025 at 2:02 PM
Reposted by Parham Eshtehardi MD
escardio.bsky.social
The evolution of CV care begins in Berlin at #ESCAIsummit2025. In just a few weeks, join global leaders, healthcare innovators & technologists to explore the digital solutions transforming the field. Register today 👉 https://ow.ly/u2XP50XknZu

#CardiologyInnovation #DigitalHealth #ESCDigital
November 3, 2025 at 9:00 AM
Reposted by Parham Eshtehardi MD
oxfordacademic.bsky.social
Join the ESC Journal Family as Editor-in-Chief of EHJ–Cardio-Oncology. This is a unique opportunity to advance global cardio-oncology research and support ESC’s mission to reduce the burden of cardiovascular disease.

Apply today: oxford.ly/3LeWLFf

@escardio.bsky.social
European Heart Journal Cardio Oncology is calling for an Editor-in-Chief.
November 1, 2025 at 8:00 AM